8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 22, 2008

SCHERING—PLOUGH CORPORATION

(Exact Name of Registrant as Specified in its Charter)

New Jersey	1-6571	22-1918501
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Schering-Plough Corporation from time to time issues Frequently Asked Questions and Answers (FAQs) that are believed to be of interest to investors. The most recent FAQs, dated February 22, 2008, are furnished as Exhibit 99.1 to this 8-K and are posted on the Schering-Plough Website at www.schering-plough.com under “investor relations/investor FAQs.”

Schering-Plough undertakes no obligation to update the FAQs and readers should note the date of information when referring to the FAQs or other historical information available on the website.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 February 22, 2008 Frequently Asked Questions and Answers

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation
By:	/s/ Steven H. Koehler
	Steven H. Koehler
	Vice-President and Controller

Date: February 22, 2008

Exhibit Index

Exhibit
Number	Description

99.1 February 22, 2008 Frequently Asked Questions and Answers

EX-99.1

Exhibit 99.1

	February 22, 2008 — Frequently Asked Questions and Answers — (FAQ’s)
	From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a compilation of recent FAQs.
Q	What are the IMS prescription volumes for VYTORIN and ZETIA?
A

U.S. Total Prescription Volume (000’s)
	January 2008
Cholesterol Management Market		20,363
Total Merck/Schering-Plough Franchise		3,194
VYTORIN		1,832
ZETIA		1,362

	Source: IMS’ National Prescription Audit Plus (NPA+)
Q	Will you provide international presciption data for VYTORIN and ZETIA?
A	Prescription data from international markets are not as robust as U.S. data and their availability varies country to country. As a result, we will not report data from international markets.
Q	Will additional ENHANCE data be presented at ACC?
A	Yes, the American College of Cardiology (ACC) has accepted the ENHANCE abstract for presentation on Sunday, March 30, 2008, following the ACC Presidential address.
Q	What is the status of sugammadex?
A	Sugammadex was filed with regulatory authorities in the U.S., EU and Japan in 2007.
	The U.S. Food & Drug Administration (FDA) has assigned priority review status to the company’s New Drug Application (NDA) for sugammadex.
	The FDA has scheduled an advisory meeting to discuss sugammadex on March 11, 2008.
	Sugammadex is specifically designed to reverse the effects of certain muscle relaxants, marketed in the United States as ZEMURON(R) (rocuronium bromide) and vecuronium bromide. Muscle relaxants are used as part of general anesthesia during surgical procedures. If approved, sugammadex will be the first in a new class of drugs known as selective relaxant binding agents that work in an entirely new and unique way to encapsulate the muscle relaxant molecule and render it inactive.

Page 1

Q	What is the status of the Peg-Interferon filing for malignant melanoma?
A	Schering-Plough submitted a supplemental Biologics License Application (sBLA) for Peg-Interferon alfa-2b to the U.S. FDA and has been granted Priority Review status for the adjuvant treatment of patients with Stage III melanoma. This was announced on January 31, 2008.
	The Priority Review designation is intended to expedite the review process for therapies that provide a significant improvement in the treatment of serious or life-threatening diseases. Based on this Priority Review status, the FDA reviews the application with the goal of taking action within six months of the sponsor’s submission of the sBLA.
	Originally, the application was to be discussed by the FDA Oncology Drugs Advisory Committee on March 12, 2008. That meeting has been postponed and a new date is still to be determined.
	DISCLOSURE NOTICE: The information in this frequently asked questions document includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the ENHANCE clinical trial and its presentation. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II, Item 1A. “Risk Factors” in Schering-Plough’s 8-K, filed February 12, 2008.

Page 2